

News Releases

All Years



Search

GO

[Advanced Search](#)

Oct 11, 2017

Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots

Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) announced today that it will be serving as a global partner for World Thrombosis Day to...

Oct 3, 2017

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on September 27, 2017, the Compensation Committee of the Board of...

Sep 12, 2017

Portola Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today the pricing of its underwritten public offering of 6,350,000 shares of...

Sep 11, 2017

Portola Pharmaceuticals Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced plans to offer, subject to market and other conditions, \$300 million...

Sep 6, 2017

Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the 2017 Morgan...

Sep 5, 2017

Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that it will host a webcast and conference call to provide an update on Bevyxxa®...

Sep 1, 2017

Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that it will host a webcast and conference call to provide an update on Bevyxxa®...

Aug 21 2017

[Aug 22, 2017](#)

Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on...

[Aug 15, 2017](#)

Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDA

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has found its...

[Aug 9, 2017](#)

Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today reported financial results and provided a corporate update for the quarter ended...

[Aug 3, 2017](#)

Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa)

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that on August 3, 2017 it resubmitted its Biologics License Application...

[Aug 2, 2017](#)

Portola Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the...

[Jul 27, 2017](#)

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on July 25, 2017, the Compensation Committee of the Board of...

[Jul 6, 2017](#)

Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee Meeting

SOUTH SAN FRANCISCO, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on...

[Jun 23, 2017](#)

U.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients

Company to hold conference call/webcast today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced the U.S. Food and Drug Administration (FDA) has approved Bevyxxa...

Jun 15, 2017

Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma

Oral, Dual SYK/JAK Inhibitor Provides Opportunity for Differentiated Activity in B-cell and other Hematological Malignancies

SOUTH SAN FRANCISCO, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced the presentation of interim data from a Phase 2a study evaluating...

May 18, 2017

Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)

SOUTH SAN FRANCISCO, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that preclinical and clinical data on cerdulatinib in relapsed/refractory...

May 9, 2017

Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)

SOUTH SAN FRANCISCO, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in patients...

May 8, 2017

Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today reported financial results and provided a corporate update for the quarter ended...

May 1, 2017

Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8

SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company's...

Mar 7, 2017

Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17

SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that new data from the pivotal Phase 3 APEX Study of the Company's...

Mar 1, 2017

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the following...

Feb 28, 2017

Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update

Conference Call Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the fourth...

Feb 21, 2017

Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the...

Feb 8, 2017

FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting

PDUFA Date of June 24, 2017 Under Priority Review

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA)'s Center for Drug...

Feb 3, 2017

Portola Pharmaceuticals Signs \$150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it has signed a \$150 million royalty agreement with HealthCare...

Jan 3, 2017

Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor webcast to review recent achievements and...

Dec 23, 2016

Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) accepted Portola's New...

Dec 19, 2016

Portola Pharmaceuticals Enters into \$50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced it has signed a \$50 million loan agreement with Bristol-Myers Squibb...

Nov 28, 2016

Portola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition

South San Francisco, Calif. (November 28, 2016) – Portola Pharmaceuticals (Nasdaq: PTLA) today announced that clinical and preclinical results from studies of all three of its investigational...

Nov 14, 2016

Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban

NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced results from three substudies of the pivotal Phase 3

Nov 12, 2016

Portola Pharmaceuticals to Host Analyst and Investor Day on November 19

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host an Analyst and Investor Day on Thursday, November 19...

Nov 7, 2016

Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions 2016

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that results of new sub-analyses of the Phase 3 APEX Study of...

Nov 7, 2016

Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update

Conference Call Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the third...

Nov 2, 2016

Portola Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Credit Suisse 24th...

Nov 1, 2016

Portola Pharmaceuticals Expands Clinical Collaboration Agreement with Daiichi Sankyo Worth Up to \$25 Million to Develop AndexXa™ (andexanet alfa) in Germany

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that it has expanded its existing clinical collaboration agreement with...

Oct 31, 2016

Portola Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Monday, November 7

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the...

Oct 25, 2016

**Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients
If Approved, Betrixaban, an FDA Fast Track-Designated Therapy, Would Be First Anticoagulant for Hospital to Home Prevention of VTE in this High-Risk Patient Population**

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and...

Oct 13, 2016

Portola Pharmaceuticals Supports “World Thrombosis Day” Campaign to Increase Awareness of Risks of Blood Clots

--Portola Working to Address Two Largest Remaining Unmet Needs in Thrombosis with Betrixaban and AndexXa™ (andexanet alfa)--

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) is committed to raising awareness of the incidence, risks and potentially...

Sep 13, 2016

Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa™ (andexanet alfa) at Neurocritical Care Society 2016 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that Phase 3 clinical data and preclinical data from studies of the...

Aug 30, 2016

Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXA-4™ Study of Factor Xa Inhibitor Antidote AndexXa™ (andexanet alfa) in Patients with Acute Major Bleeding

--AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors; Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours--

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced interim results from the ongoing Phase 3b/4 ANNEXA™-4 study of...

Aug 26, 2016

Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at European Society of Cardiology 2016 Congress

Company to Host Webcast of Investor Event with Drs. Stuart J. Connolly and C. Michael Gibson to Discuss Data on Tuesday, August 30

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA™-4 trial of...

Aug 19, 2016

Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa™ (andexanet alfa), a Factor Xa Inhibitor Antidote

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the MAA for IndexXa™ (andexanet alfa; trade name in the United...

Aug 17, 2016

Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)

-- Conference call on August 18 at 8:30 am ET --

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food...

Aug 9, 2016

Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Conference Call Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the quarter...

Aug 2, 2016

Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host

Conference Call on Tuesday, August 9

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the...

Jun 1, 2016

Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings

SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is...

May 31, 2016

Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37th...

May 27, 2016

Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting

--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016--

MONTPELLIER, France, and SOUTH SAN FRANCISCO, Calif. , May 27, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) announced that the full results of its pivotal Phase 3 APEX...

May 23, 2016

Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting

Webcast of Investor Event to Discuss Phase 3 APEX Data to be Held on Friday, May 27

SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be...

Show 50  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) 



<https://investors.portola.com/news-releases?l=50&o=100>